Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and chemotherapy in gBRCA-mutated TNBC
NCT05834582Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in triple-negative breast cancer (TNBC), sponsored by Jiangsu Provincial People's Hospital. Started Apr 2023; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05834582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05834582.